New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:05 EDTRNNRexahn initiated with an Outperform at Burrill
Target $1.00. Burrill believes Rexahn’s pipeline in oncology and CNS disorders is undervalued.
News For RNN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
09:11 EDTRNNRexahn announces positive preclinical data on Supinoxin
Rexahn announced that it presented preclinical data on Supinoxin at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia. In the present study, Supinoxin was shown to dose-dependently decrease the migration of human triple negative breast cancer cells in a preclinical model of cancer cell metastasis. Supinoxin is currently in a Phase I dose-escalation clinical trial in cancer patients with solid tumors with clinical data expected in the first half of 2015.
April 20, 2015
09:20 EDTRNNRexahn identifies RX-3117 biomarker
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use